Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published in 2008

There are 2390 items in the Healthy Skepticism Library that were published in 2008.

Page 24 of 24 pages ‹ First  < 22 23 24

Boyd MA, Roth K, Ralls SA, Chambers DW.
Beginning the discussion of commercialism in dentistry.
J Calif Dent Assoc 2008 Jan; 36:(1):57-65

The indifferent industry: Big Pharma, essential medicines and Africa’s sick
: Forum for African Investigative Reporters (FAIR) 2008 Jan

Islam MS, Farah SS.
Characteristics and Reliability of Online References Cited in the Pharmaceutical Promotional Brochures of Bangladesh
eHealth International Journal 2008 Jan; 4:(1):1-5

Islam MS, Farah SS.
Drug promotional brochure as a source of drug information in Bangladesh: a critical analysis of the brochures for the authenticity of information.
Calicut Medical Journal 2008 Jan-Mar; 6:(1):e5

Thomas V.
Drugs: prescription and promotion in third world countries
Calicut Medical Journal 2008 Jan-Mar; 6:(1):e1

Huff-Rousselle M
Global pharmaceuticals: ethics, markets, practices [Book review]
The International Journal of Health Planning and Management 2008 Jan; 23:(1):79-82

Stossel TP.
Response to AMA's Council on Ethical and Judicial Affairs draft report on 'Ethical guidance for physicians and the profession with respect to industry support for professional education in medicine'
Medscape J Med 2008 12; 10:(6):137

Stossel TP.
A biopsy of financial conflicts of interest in medicine.
Surgery 2008; 143:(2):193-8

Herndon MB, Schwartz LM, Woloshin S, Anthony D, Gallagher P, Fowler FJ, Fisher E.
Older patients perceptions of 'unnecessary' tests and referrals: a national survey of Medicare beneficiaries.
J Gen Intern Med 2008; 23:(10):1547-54

Henderson J, Miller G, Pan Y, Britt H.
The effect of advertising in clinical software on general practitioners’ prescribing behaviour
The Medical Journal of Australia 2008; 188:(1):15-20

Harvey K, Korczak VS, Marron LJ, Newgreen DB.
Commercialism, choice and consumer protection: regulation of complementary medicines in Australia
The Medical Journal of Australia 2008; 188:(1):21-25

Raftery JP.
Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand
The Medical Journal of Australia 2008; 188:(1):26-28

Dach C.
The Media's New Aesthetic: Why TV is About to Have a Major Mood Swing.
Adbusters 2008

Lin HY, Liao CC, Cheng SH, Wang PC, Hsueh YS.
Association of potentially inappropriate medication use with adverse outcomes in ambulatory elderly patients with chronic diseases: experience in a taiwanese medical setting.
Drugs Aging 2008; 25:(1):49-59

Adler NE, Koschorreck J, Rechenberg B.
Environmental impact assessment and control of pharmaceuticals: the role of environmental agencies.
Water Sci Technol 2008; 57:(1):91-7

Montagne M.
Drugs on the internet. I: introduction and web sites on psychedelic drugs.
Subst Use Misuse. 2008; 43:(1):17-25

Woodcock J, Woosley R.
The FDA critical path initiative and its influence on new drug development.
Annu Rev Med 2008; 59:1-12:

Coombes ID, Stowasser DA, Coombes JA, Mitchell C.
Why do interns make prescribing errors? A qualitative study
MJA 2008; 18:(2):89-94

Millar JA, Silla RC, Lee GE, Berwick A.
The national inpatient medication chart: critical audit of design and performance at a tertiary hospital
MJA 2008; 188:(2):95-99

Hassali MAA, Stewart K, Kong DCM.
A national survey on knowledge and perceptions of senior medical students in Australia about generic medicines
MJA 2008; 188:(2):123-4

Loewenberg S.
Drug company trials come under increasing scrutiny
The Lancet 2008; 371:(9608):191-2

Etwel FA, Rieder MJ, Bend JR, Koren G.
A Surveillance Method for the Early Identification of Idiosyncratic Adverse Drug Reactions.
Drug Saf 2008; 31:(2):169-180

Layton D, Souverein PC, Heerdink ER, Shakir SA, Egberts AC.
Evaluation of Risk Profiles for Gastrointestinal and Cardiovascular Adverse Effects in Nonselective NSAID and COX-2 Inhibitor Users : A Cohort Study Using Pharmacy Dispensing Data in The Netherlands.
Drug Saf 2008; 31:(2):143-58

Morgan S, Cunningham C.
The Effect of Evidence-Based Drug Coverage Policies on Pharmaceutical R&D: A Case Study from British Columbia
Longwoods Publishing 2008;

Donner-banzhoff N, Sönnichsen A.
Strategies for prescribing statins
BMJ 2008; 336:(7639):288

Kapsak WR, Schmidt D, Childs NM, Meunier J, White C.
Consumer perceptions of graded, graphic and text label presentations for qualified health claims.
Crit Rev Food Sci Nutr 2008; 48:(3):248-56

Matthews RA.
Medical progress depends on animal models - doesn't it?
J R Soc Med 2008; 101:(2):95-98

Morgan S, Lopert R, Greyson D.
Toward a definition of pharmaceutical innovation
Open Medicine 2008; 2:(1):epub

Petersen M.
Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs
New York: Sarah Crichton Books/Farrar, Straus and Giroux 2008

Griffiths S.
Pharmaceutical branding: 'To brand or not to brand'
Journal of Medical Marketing 2008; 8:(2):113–118

Raasch C.
Launching a fighter brand to cushion patent expiry: The case of Zocor
Journal of Medical Marketing 2008; 8:(2):119–126

Ware C, Buckwell C, Small S, Wood R.
Activation of evidence: A new approach to knowledge translation and closing the clinical care gap
Journal of Medical Marketing 2008; 8:(2):127–136

Heiens RA, McGrath LC, Leach RT.
The impact of intangible assets and expenditures on holding period returns in the pharmaceutical industry
Journal of Medical Marketing 2008; 8:(2):151–158

Naboko D, Petkova V, Dimitrova Z.
Combination of marketing strategies for increase of anti-smoking drugs sales
Journal of Medical Marketing 2008; 8:(2):144–150

Ham CD, Jun JW, Lee H-S.
How to reach consumers in a market where DTC is not allowed
Journal of Medical Marketing 2008; 8:(2):159–168

Kruszewski SP, Paczynski RP, Marzana BIALY.
State Medical Board Responses To An Inquiry On Physician Researcher Misconduct
Journal of Medical Licensure and Discipline 2008; 94:(1):

Alkhateeb , Fma .
Influences on physicians' adoption of e-detailing

Huddle TS.
Drug Reps and the Academic Medical Center: a case for management rather than prohibition.
Perspect Biol Med 2008 Spr; 51:(2):251-60

Bush A.
Regulating spoons
Eur Respir J 2008; 31:(4):699-700

Weinbach D.
10 steps to reaching physicians.
Mark Health Serv 2008 Spr; 28:(1):41-2

Lexchin J.
Drug Approval Times and User Fees: An International Perspective in a Changing World
Pharm Med 2008; 22:(1):1-11

Cassels A, Lexchin J.
How well do Canadian media outlets convey medical treatment information?
Open Medicine 2008; 2:(2):epub

Kurzlechner W.
Ärzte fassen sich an die eigene Nase
Pharmazeutische Zeitung 2008

Huskamp HA, Donohue JM, Koss C, Berndt ER, Frank RG.
Generic Entry, Reformulations and Promotion of SSRIs in the US.
Pharmacoeconomics 2008; 26:(7):603-16

Schwartz MI.
To ban or not to ban--that is the question: the constitutionality of a moratorium on consumer drug advertising.
Food Drug Law J 2008; 63:(1):1-33

Charter challenge on drugs ads: A challenge in the wrong direction
The Canadian Women's Health Network Magazine 2008

Lippman A, Rochon Ford A, O’Grady K.
Barbara Seaman (1935-2008): Pioneer in the women’s health movement
The Canadian Women's Health Network Magazine 2008

Taylor E.
Illegal human growth hormone markets. Issues in controlling online drug sales and advertising
Journal of Legal Medicine 2008;

Montoya ID, Lee-Dukes G, Shah D.
Direct-to-consumer advertising: its effects on stakeholders.
J Allied Health 2008 Sum; 37:(2):116-20

Ecks S.
Global Pharmaceutical Markets and Corporate Citizenship: The Case of Novartis' anti-cancer drug Glivec
Biosocieties 2008; (3):165-181

Giampaolo V, Riccardo R, Roberto S.
Drugs in the newspapers.
Drugs 2008; 68:(7):1017-8

Nguyen ES.
Weight loss testimonials: a critique of potential FTC restrictions on diet advertising.
Food Drug Law J. 2008; 63:(2):493-507

Carrigan N, Raynor DK, Knapp P.
Adequacy of patient information on adverse effects: an assessment of patient information leaflets in the UK.
Drug Saf 2008; 31:(4):305-12

Haines IE, Olver IN.
Are self-regulation and declaration of conflict of interest still the benchmark for relationships between physicians and industry?
eMJA 2008; 189:(5):263-266

Joseph M, Spake DF, Finney Z.
Consumer attitudes toward pharmaceutical direct-to-consumer advertising: An empirical study and the role of income
International Journal of Pharmaceutical and Healthcare Marketing 2008; 2:(2):117 - 133

Demaria AN.
Continuing education, industry, and physicians
J Am Coll 2008; 52:1035-1036.

Healy D.
Our Censored Journals
Mens Sana Monographs 2008; 6:(1):244-256;year=2008;volume=6;issue=1;spage=244;epage=256;aulast=Healy

Civaner M.
[A proposal for the prevention of ethical problems related to drug promotion: a national network for drug information].
Turk Psikiyatri Derg. 2008; 19:(3):310-7

Jureidini J, Mintzes B, Raven M.
Does direct-to-consumer advertising of antidepressants lead to a net social benefit?
Pharmacoeconomics 2008; 26:(7):557-66;

Morrow LE, Kollef MH.
Probiotics in the intensive care unit: why controversies and confusion abound.
Crit Care. 2008; 12:(3):160

Lee PE, Fischer HD, Rochon PA, Gill SS, Herrmann N, Bell CM.
Published randomized controlled trials of drug therapy for dementia
Journal of Clinical Epidemiology 2008; 61:1152-1160

Rutter P, Gilbody S.
The European pharmaceutical industry: coming to a screen near you?
J R Soc Med 2008; 101:(10):485–488.

Pollock A.
Pharmaceutical meaning-making beyond marketing: racialized subjects of generic thiazide.
J Law Med Ethics. 2008 Fal; 36:(3):530-6

Hudec R, Kriska M, Bozekova L, Foltan V.
Comparison of NSAID consumption in Slovakia, Finland and Norway.
Bratisl Lek Listy. 2008; 109:(8):370-3

Lemmens T, Luther L.
Financial conflict of interest in medical research
Singer PA, Viens AM. The Cambridge Textbook of Bioethics New York: Cambridge University Press 2008

Brezis M.
Big pharma and health care: unsolvable conflict of interests between private enterprise and public health.
Isr J Psychiatry Relat Sc 2008; 45:(2):83-9;

Ramsey S, Scoggins J.
Commentary: Practicing on the Tip of an Information Iceberg Evidence of Underpublication of Registered Clinical Trials in Oncology
The Oncologist 2008; 13:925–929

Glaeske G.
[Why are some drugs so expensive? The price policy of pharmaceutical companies--'digging the grave of our health insurance-system'?]
Z Evid Fortbild Qual Gesundhwes 2008; 102:(4):269-77

Parrott R, Volkman J, Ghetian C, Weiner J, Raup-Krieger J, Parrott J.
Memorable messages about genes and health: implications for direct-to-consumer marketing of genetic tests and therapies.
Health Mark Q. 2008; 25:(1-2):8-32

14 Drugs Identified as Most Urgently Needing Study for Off-Label Use, Stanford Professor Says
Fierce Biotech 2008

Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart A, Choudhry NK, Shrank WH.
Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-analysis
JAMA 2008; 300:(21):2514-2526.

Shani S, Yahalom Z.
The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
Food Drug Law J. 2008; 63:(3):701-11

Segman R, Weizman A
Drug industry, psychopharmacology, and mental health care needs: where do we go from here?
Isr J Psychiatry Relat Sci. 2008; 45:(2):71-9

Jacobstein JM.
Federal regulatory pre-emption of state tort claims against the manufacturers of medical devices and pharmaceutical drugs.
J Law Med Ethics. 2008 Fal; 36:(3):594-7

Hogarth S, Javitt G, Melzer D.
The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues.
Annu Rev Genomics Hum Genet 2008; 9:161-82

Fugh-Berman A, Dodgson SJ.
Ethical considerations of publication planning in the pharmaceutical industry
Open Medicine 2008; 2:(4):

Ulaş H, Bınbay T, Alptekın K.
[Financial Conflict of Interest in Clinical Psychiatry Studies: A Review].
Turk Psikiyatri Derg. 2008 Win; 19:(4):418-426

Lexchin J
Clinical trials in Canada: whose interests are paramount?
Int J Health Serv 2008; 38:(3):525-42

Health Action International- Asia Pacific
Multi country Survey on Banned and Restricted Pharmaceuticals
Colombo, Sri Lanka: Health Action International- Asia Pacific 2008 August

International Comparative Legal Guide Series: Pharmaceutical Advertising 2008
: Global Legal Group Limited 2008

Matheson A.
Corporate Science and the Husbandry of Scientific and Medical Knowledge by the Pharmaceutical Industry
BioSocieties 2008; 3:355–382

Norey E, Simone TM, Mousa SA.
The Impact of Direct-to-Consumer Advertised Drugs on Drug Sales in the US and New Zealand.
Appl Health Econ Health Policy. 2008; 6:(2-3):93-102

National Task Force on CME Provider/Industry Collaboration
Continuing Medical Education: Addressing Conflict of Interest (COI)
: National Task Force on CME Provider/Industry Collaboration 20081:(2):

Campos Alves SM.
Processo de participação da sociedade civil nas consultas públicas realizadas pela Agência Nacional de Vigilância Sanitária - Anvisa
Departmento de Servico Social Brasília: Universidade de Brasilia 2008

Healy D
Mania: A Short History of Bipolar Disorder. Baltimore: Johns Hopkins University Press 2008

Higgins J
Assessing risk of bias in included studies
Altman DG, Higgins JPT Cochrane handbook for systematic reviews of interventions Version 501 Chichester, UK: Wiley-Blackwell 2008

Sladek RM, Bond MJ, Phillips PA.
Why don't doctors wash their hands? A correlational study of thinking styles and hand hygiene
Am J Infect Control 2008; 36:(6):399-406

de Beaufort I, Vandamme S.
'No willpower required'. The slimming industry and the right to sell dreams
Med Law 2008 Mar; 27:(1):215-28.

Sladek RM, Phillips PA, Bond MJ.
Measurement properties of the Inventory of Cognitive Bias in Medicine (ICBM).
BMC Med Inform Decis Mak 2008 28; 8:20:

Page 24 of 24 pages ‹ First  < 22 23 24


  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Click to Register

(read more)

Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

Cases of wilful misrepresentation are a rarity in medical advertising. For every advertisement in which nonexistent doctors are called on to testify or deliberately irrelevant references are bunched up in [fine print], you will find a hundred or more whose greatest offenses are unquestioning enthusiasm and the skill to communicate it.

The best defence the physician can muster against this kind of advertising is a healthy skepticism and a willingness, not always apparent in the past, to do his homework. He must cultivate a flair for spotting the logical loophole, the invalid clinical trial, the unreliable or meaningless testimonial, the unneeded improvement and the unlikely claim. Above all, he must develop greater resistance to the lure of the fashionable and the new.
- Pierre R. Garai (advertising executive) 1963